Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can Zytiga Prevail In Pre-Chemo Prostate Cancer Without Proof Of Survival Benefit?

Executive Summary

J&J’s abiraterone gains FDA clearance for the new claim without statistical significance for its 5-month survival advantage, but Medivation’s Xtandi is waiting in the wings – and its pre-chemo trial, PREVAIL, is likely to show a significant effect.

You may also be interested in...



J&J’s Zytiga Secures Survival Claim For Early Metastatic Prostate Cancer

Labeling now indicates a statistically significant 19% reduction in risk of death for Zytiga in chemo-naïve metastatic prostate cancer, similar to the 23% reduction just reported in long-term analysis of Medivation/Astellas’ competing Xtandi in the same population.

What Not To Do: FDA Reviewer Talks Cancer Drug Development Mistakes

Using anonymous examples at the recent AACR meeting, FDA’s Tatiana Prowell highlights mistakes made and lessons learned in oncology drug reviews.

Medivation/Astellas Will Be Ready For Xtandi To Enter Pre-Chemo Prostate Cancer Setting

The oncology drug has been submitted for approval in the larger chemotherapy-naïve patient population and Medivation intends to increase its sales force to support the launch.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel